Company research
PDS Biotechnology Corp
CIK 1472091Updated Sep 27, 2026
SecurityPDSB · NASDAQ · equity
Name history
Edge Therapeutics, Inc. · through Mar 18, 2019
PDSB price & chart
Loading TradingView…
NASDAQ:PDSB on TradingView ↗About the company
We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our Versamune® T cell activator and Versamune® in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. In addition, we are developing the Infectimune® T cell-activator in infectious diseases.
In the news
Biotech Stocks Rally as Oncology Market Targets $866B by 2034 News provided by Equity Insider Aug 14, 2025, 12:30 ET Share this article Share to X Share this article Share to X Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , Aug. 14, 2025 /PRNewswire/ -- E ↗
Recent filings
Other Events
Items 8.01, 9.01
SCHEDULE 13D - filed by Nant Capital, LLC regarding PDS Biotechnology Corp
Other Events
Items 8.01, 9.01
Termination of a Material Definitive Agreement · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure · Other Events
Items 1.02, 5.02, 7.01, 8.01, 9.01
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 3.02, 7.01, 9.01
Show 5 more recent filings
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Items 1.01, 2.03, 9.01
Costs Associated with Exit or Disposal Activities · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 2.05, 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 30,494,083Source | 45,358,657Source | 59,390,080Source | 77,007,923Source |
| Property, Plant and Equipment, NetUSD | 120,184Source | 142,020Source | 134,132Source | 0Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 26,711,969Source | 41,689,591Source | 56,560,517Source | 73,820,160Source |
| Assets, CurrentUSD | 28,254,085Source | 45,054,443Source | 59,055,075Source | 76,480,390Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,542,116Source | 3,364,852Source | 2,494,558Source | 2,660,230Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | 0Source | 152,645Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 21,242,250Source | 26,353,809Source | 33,259,133Source | 33,005,893Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 18,111Source | 12,536Source | 10,921Source | 9,956Source |
| Additional Paid in CapitalUSD | 225,840,226Source | 201,103,311Source | 170,620,641Source | 145,550,491Source |
| Retained Earnings (Accumulated Deficit)USD | -216,606,504Source | -182,110,999Source | -144,500,615Source | -101,558,417Source |
| Stockholders' Equity Attributable to ParentUSD | 9,251,833Source | 19,004,848Source | 26,130,947Source | 44,002,030Source |
| Liabilities and EquityUSD | 30,494,083Source | 45,358,657Source | 59,390,080Source | 77,007,923Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 9,483,214Source | 17,087,201Source | 13,629,977Source | 9,821,036Source |
| Operating Lease, Liability, CurrentUSD | — | — | 0Source | 231,429Source |
| Accounts Payable, CurrentUSD | 3,574,448Source | 1,684,868Source | 6,982,824Source | 1,219,287Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 0Source | 0Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 742,227Source | 2,841,214Source | 2,424,692Source | 8,313,708Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 4,106,606Source | 6,848,193Source | 7,614,321Source | 5,196,156Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 1,889,580Source | -5,297,956Source | 5,763,537Source | -90,116Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -27,752,012Source | -35,030,223Source | -33,636,136Source | -25,709,706Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 0Source | -29,000Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 0Source | 29,000Source | — | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | 0Source | 270,959Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 12,774,390Source | 20,188,297Source | 16,376,493Source | 34,287,244Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 26,711,969Source | 41,689,591Source | 56,560,517Source | 73,820,160Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 2,921,359Source | 3,556,662Source | 3,535,071Source | 852,221Source |
| Income Taxes Paid, NetUSD | -1,162,953Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 4,106,606Source | 6,848,193Source | 7,614,321Source | 5,196,156Source |
| DepreciationUSD | 21,836Source | 21,112Source | 17,359Source | 86Source |
| Gain (Loss) on Extinguishment of DebtUSD | -1,107,004Source | — | — | — |
| General and Administrative ExpenseUSD | 12,518,127Source | 13,755,671Source | 15,282,450Source | 12,241,394Source |
| Income Tax Expense (Benefit)USD | -1,169,820Source | -869,169Source | -1,406,019Source | -1,198,905Source |
| InterestExpenseNonoperatingUSD | 5,338,607Source | 4,673,174Source | — | — |
| Investment Income, InterestUSD | 1,217,241Source | 2,514,816Source | 2,902,939Source | 935,180Source |
| Net Income (Loss) Attributable to ParentUSD | -34,495,505Source | -37,610,384Source | -42,942,198Source | -40,854,855Source |
| Operating ExpensesUSD | 31,543,959Source | 36,321,195Source | 43,045,234Source | 41,672,421Source |
| Operating Lease, ExpenseUSD | — | — | — | 241,029Source |
| Pension Expense (Reversal of Expense), NoncashUSD | — | — | — | 0Source |
| Proceeds from Issuance of Common StockUSD | 9,709,064Source | 22,595,001Source | 16,126,851Source | 9,856,116Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 774,091Source | 308,942Source | 151,416Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -31,543,959Source | -36,321,195Source | -43,045,234Source | -41,672,421Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -35,665,325Source | -38,479,553Source | -44,348,217Source | -42,053,760Source |
| Income Tax Expense (Benefit)USD | -1,169,820Source | -869,169Source | -1,406,019Source | -1,198,905Source |
| Net Income (Loss) Attributable to ParentUSD | -34,495,505Source | -37,610,384Source | -42,942,198Source | -40,854,855Source |
| Earnings Per Share, BasicUSD per share | -0.74Source | -1.03Source | -1.39Source | -1.43Source |
| Earnings Per Share, DilutedUSD per share | -0.74Source | -1.03Source | -1.39Source | -1.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 46,384,280Source | 36,452,707Source | 30,952,060Source | 28,599,221Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 46,384,280Source | 36,452,707Source | 30,952,060Source | 28,599,221Source |
| Interest Expense (non-operating)USD | 5,338,607Source | 4,673,174Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | -1,169,820Source | — | — | — |
| General and Administrative ExpenseUSD | 12,518,127Source | 13,755,671Source | 15,282,450Source | 12,241,394Source |
| Interest ExpenseUSD | — | — | 4,205,922Source | 1,316,519Source |
| Interest Expense, DebtUSD | — | 4,659,118Source | 4,187,075Source | 1,288,776Source |
| Interest Income (Expense), Nonoperating, NetUSD | -4,121,366Source | -2,158,358Source | -1,302,983Source | -381,339Source |
| Investment Income, InterestUSD | 1,217,241Source | 2,514,816Source | 2,902,939Source | 935,180Source |
| Operating ExpensesUSD | 31,543,959Source | 36,321,195Source | 43,045,234Source | 41,672,421Source |
| Operating Lease, ExpenseUSD | — | — | — | 241,029Source |
| Research and Development ExpenseUSD | 19,025,832Source | 22,565,524Source | 27,762,784Source | 29,431,027Source |
Offerings
Registration 333-297386
- Offering price
- at-the-market
- Ticker
- PDSB
Filing attachments
ef20082545_ex99-1.htm · 8-K · 2026-09-22
Exhibit 99.1 PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101 PRINCETON, N.J., September 22, 2026 -- PDS Biotechno…
Read attachment ↗ef20082538_ex99-1.htm · 8-K · 2026-09-21
Exhibit 99.1 Overview of PDS Biotech Drug Development Programs (Oncology) NASDAQ: PDSB September 2026 Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and exp…
Read attachment ↗ef20081956_ex99-1.htm · 8-K · 2026-09-14
EX-99.1 2 ef20081956_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors Gross Proceeds of $11.3 Million at Initial Closing Transaction Led by Dr. Patrick Soon-Shiong, Founder of NantWorks Princeton, NJ, September 14, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on dev…
Read attachment ↗ef20081705_ex4-1.htm · 8-K · 2026-09-08
EX-4.1 2 ef20081705_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS PRE-FUNDED WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS PRE-FUNDED WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT T…
Read attachment ↗ef20081705_ex4-2.htm · 8-K · 2026-09-08
EX-4.2 3 ef20081705_ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK (OR IN LIEU THEREOF, PRE-FUNDED WARRANTS (AS DEFINED BELOW)) ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES H…
Read attachment ↗ef20081705_ex99-1.htm · 8-K · 2026-09-08
EX-99.1 7 ef20081705_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks Dr. Soon-Shiong will Join PDS Biotech’s Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors Princeton, NJ, September 8, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted …
Read attachment ↗